Skip to Main Navigation
Skip to Page Content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Share This:
https://ntp.niehs.nih.gov/go/18977

Water disinfection model (Bromodichloromethane): Target Organs and Levels of Evidence for GMM-05

Toxicology Studies of Bromodichloromethane (CASRN 75-27-4) in Genetically Modified (FVB Tg.AC Hemizygous) Mice (Dermal, Drinking Water, and Gavage Studies) and Carcinogenicity Studies of Bromodichloromethane in Genetically Modified [B6.129-Trp53tm1Brd (N5) Haploinsufficient] Mice (Drinking Water and Gavage Studies)

Chemical (Study Title)
CASRN
Peer Review Date Primary Uses Route/Exposure Levels Study Laboratory
Water disinfection model (Bromodichloromethane)
75-27-4
09/27/2005 Solvent. Chemical intermediate. Flame retardant. Special initiative using the transgenic mouse model in methods development. Topical Application
0, 64, 128, and 256 mg/kg
Battelle Columbus Laboratory

Levels of evidence information for Dermal and Genetic Toxicology Studies of Bromodichloromethane in Tg.AC Hemizygous Mice
  Male Tg.AC Hemizygous Mice Female Tg.AC Hemizygous Mice
  26 Weeks 39 Weeks 26 Weeks 39 Weeks
Neoplastic Lesions None None None None
Non-Neoplastic Lesions None None None None




Chemical (Study Title)
CASRN
Peer Review Date Primary Uses Route/Exposure Levels Study Laboratory
Water disinfection model (Bromodichloromethane)
75-27-4
09/27/2005 Solvent. Chemical intermediate. Flame retardant. Special initiative using the transgenic mouse model in methods development. Dosed-Water
0, 175, 350, or 700 mg/L
Battelle Columbus Laboratory

Levels of evidence information for Drinking Water and Genetic Toxicology Studies of Bromodichloromethane in p53 Haploinsufficient Mice
  Male P53 +/- (C57BL/6) Mice Female P53 +/- (C57BL/6) Mice
  26 Weeks 42 Weeks 26 Weeks 42 Weeks
Levels of Evidence No Evidence No Evidence No Evidence No Evidence
Neoplastic Lesions None None None None
Non-Neoplastic Lesions
  • Kidney: tubule degeneration
  • Kidney: tubule degeneration
  • Liver: hepatocyte fatty change
None

Levels of evidence information for Drinking Water and Genetic Toxicology Studies of Bromodichloromethane in Tg.AC Hemizygous Mice
  Male Tg.AC (FVB/N) Hemizygous Mice Female Tg.AC (FVB/N) Hemizygous Mice
  26 Weeks 42 Weeks 26 Weeks 42 Weeks
Neoplastic Lesions None None None None
Non-Neoplastic Lesions
  • Kidney: nephropathy; tubule degeneration
  • Kidney: nephropathy
  • Liver: hepatocyte fatty change; hepatocyte cytoplasmic vacuolization
  • Liver: hepatocyte fatty change




Chemical (Study Title)
CASRN
Peer Review Date Primary Uses Route/Exposure Levels Study Laboratory
Water disinfection model (Bromodichloromethane)
75-27-4
09/27/2005 Solvent. Chemical intermediate. Flame retardant. Special initiative using the transgenic mouse model in methods development. Gavage
0, 25, 50, or 100 mg/kg
Battelle Columbus Laboratory

Levels of evidence information for Gavage and Genetic Toxicology Studies of Bromodichloromethane in p53 Haploinsufficient Mice
  Male P53 +/- (C57BL/6) Mice Female P53 +/- (C57BL/6) Mice
  26 Weeks 41 Weeks 26 Weeks 41 Weeks
Levels of Evidence No Evidence No Evidence No Evidence No Evidence
Neoplastic Lesions None None None None
Non-Neoplastic Lesions
  • Kidney: tubule degeneration
  • Kidney: tubule degeneration
  • Liver: hepatocyte fatty change
  • Liver: hepatocyte fatty change


Levels of evidence information for Gavage and Genetic Toxicology Studies of Bromodichloromethane in Tg.AC Hemizygous Mice
  Male Tg.AC (FVB/N) Hemizygous Mice Female Tg.AC (FVB/N) Hemizygous Mice
  26 Weeks 41 Weeks 26 Weeks 41 Weeks
Neoplastic Lesions None None
  • Forestomach: multiple squamous cell papilloma 3/15 5/15 6/15 11/15
  • Forestomach: multiple squamous cell papilloma 1/10 6/10 5/10 9/10
Non-Neoplastic Lesions
  • Kidney: tubule degeneration
  • Kidney: tubule degeneration
  • Liver: hepatocyte fatty change; hepatocyte cytoplasmic vacuolization
  • Liver: hepatocyte fatty change; hepatocyte cytoplasmic vacuolization